Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$25.70 USD
-0.26 (-1.00%)
Updated Sep 13, 2024 02:56 PM ET
2-Buy of 5 2
A Value A Growth C Momentum A VGM
Cash flow Statements
Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 281.00 | 233.00 | 544.00 | 558.00 | 491.00 |
Depreciation/Amortization & Depletion | 241.00 | 359.00 | 133.00 | 79.00 | 90.00 |
Net Change from Assets/Liabilities | 80.00 | -131.00 | -30.00 | -208.00 | -44.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.00 | 69.00 | -9.00 | 35.00 | -65.00 |
Net Cash From Operating Activities | 608.00 | 530.00 | 638.00 | 464.00 | 472.00 |
Property & Equipment | -151.00 | -137.00 | -145.00 | -172.00 | -117.00 |
Acquisition/ Disposition of Subsidiaries | -98.00 | -1.00 | 0.00 | 0.00 | -8.00 |
Investments | -26.00 | -388.00 | 6.00 | -3.00 | 8.00 |
Other Investing Activities | -58.00 | -81.00 | -99.00 | -108.00 | -34.00 |
Net Cash from Investing Activities | -333.00 | -607.00 | -238.00 | -283.00 | -151.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | -300.00 | 0.00 | -375.00 | 0.00 |
Issuance (Repayment) of Debt | -63.00 | 439.00 | -35.00 | 171.00 | 8.00 |
Increase (Decrease) Short-Term Debt | -40.00 | 8.00 | -79.00 | 49.00 | -18.00 |
Payment of Dividends & Other Distributions | -141.00 | -128.00 | -121.00 | -110.00 | -99.00 |
Other Financing Activities | -93.00 | -77.00 | -52.00 | -33.00 | -46.00 |
Net Cash from Financing Activities | -337.00 | -58.00 | -287.00 | -298.00 | -155.00 |
Effect of Exchange Rate Changes | -3.00 | -21.00 | -10.00 | -2.00 | 0.00 |
Net Change In Cash & Equivalents | -65.00 | -156.00 | 103.00 | -119.00 | 166.00 |
Cash at Beginning of Period | 270.00 | 426.00 | 323.00 | 442.00 | 276.00 |
Cash at End of Period | 205.00 | 270.00 | 426.00 | 323.00 | 442.00 |
Diluted Net EPS | 0.85 | 0.84 | 1.81 | 1.81 | 2.00 |
Fiscal Year End for Hikma Pharmaceuticals Plc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | NA | 281.00 | NA | 202.00 |
Depreciation/Amortization & Depletion | NA | NA | 241.00 | NA | 137.00 |
Net Change from Assets/Liabilities | NA | NA | 80.00 | NA | -115.00 |
Net Cash from Discontinued Operations | NA | NA | 0.00 | NA | NA |
Other Operating Activities | NA | NA | 6.00 | NA | -2.00 |
Net Cash From Operating Activities | NA | NA | 608.00 | NA | 222.00 |
Property & Equipment | NA | NA | -151.00 | NA | -84.00 |
Acquisition/ Disposition of Subsidiaries | NA | NA | -98.00 | NA | NA |
Investments | NA | NA | -26.00 | NA | -4.00 |
Other Investing Activities | NA | NA | -58.00 | NA | -31.00 |
Net Cash from Investing Activities | NA | NA | -333.00 | NA | -119.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | 0.00 | NA | NA |
Issuance (Repayment) of Debt | NA | NA | -63.00 | NA | -9.00 |
Increase (Decrease) Short-Term Debt | NA | NA | -40.00 | NA | 33.00 |
Payment of Dividends & Other Distributions | NA | NA | -141.00 | NA | -82.00 |
Other Financing Activities | NA | NA | -93.00 | NA | -40.00 |
Net Cash from Financing Activities | NA | NA | -337.00 | NA | -98.00 |
Effect of Exchange Rate Changes | NA | NA | -3.00 | NA | -3.00 |
Net Change In Cash & Equivalents | NA | NA | -65.00 | NA | 2.00 |
Cash at Beginning of Period | NA | NA | 270.00 | NA | 270.00 |
Cash at End of Period | NA | NA | 205.00 | NA | 272.00 |
Diluted Net EPS | NA | NA | NA | NA | NA |